{"id":453,"date":"2026-08-27T10:31:11","date_gmt":"2026-08-27T10:31:11","guid":{"rendered":"https:\/\/nhdbio.com\/tesamorelin-hiv-lipodystrophy-randomized-trials\/"},"modified":"2026-08-28T07:31:46","modified_gmt":"2026-08-28T07:31:46","slug":"essais-cliniques-randomises-sur-la-tesamoreline-et-la-lipodystrophie-liee-au-vih","status":"publish","type":"post","link":"https:\/\/nhdbio.com\/fr\/tesamorelin-hiv-lipodystrophy-randomized-trials\/","title":{"rendered":"Lipodystrophie associ\u00e9e \u00e0 Tesamorelin et HIV\u00a0: ce que les essais randomis\u00e9s ont mesur\u00e9"},"content":{"rendered":"
Tesamorelin est un analogue du facteur de lib\u00e9ration de l'hormone de croissance avec une base de preuves cliniques d\u00e9finie chez les adultes atteints de lipodystrophie associ\u00e9e \u00e0 HIV. Ce contexte sp\u00e9cifique de population et de crit\u00e8re d'\u00e9valuation est essentiel\u00a0: les preuves ne doivent pas \u00eatre g\u00e9n\u00e9ralis\u00e9es dans une vaste all\u00e9gation de perte de poids du consommateur.<\/p>
Points cl\u00e9s \u00e0 retenir<\/h2>
Des \u00e9tudes pivots ont mesur\u00e9 le tissu adipeux visc\u00e9ral chez les adultes pr\u00e9sentant une accumulation de graisse abdominale associ\u00e9e \u00e0 HIV.<\/li>
L'\u00e9tiquette FDA indique que le produit approuv\u00e9 n'est pas indiqu\u00e9 pour la gestion de la perte de poids.<\/li>
Les preuves de produits approuv\u00e9s n'\u00e9tablissent pas l'\u00e9quivalence d'un mat\u00e9riel de recherche fourni de mani\u00e8re ind\u00e9pendante.<\/li><\/ul><\/div><\/div>Illustration \u00e9ditoriale originale de l'examen de l'imagerie abdominale dans une \u00e9tude sur la lipodystrophie associ\u00e9e \u00e0 HIV\u00a0; aucun patient ni produit n'est repr\u00e9sent\u00e9.<\/figcaption><\/figure>
Le contexte biologique et clinique<\/h2>
Tesamorelin est un analogue du facteur de lib\u00e9ration de l'hormone de croissance. Dans le contexte \u00e9tudi\u00e9, il stimule la lib\u00e9ration hypophysaire de l'hormone de croissance et augmente la signalisation IGF-1. Les essais pertinents ont recrut\u00e9 des personnes vivant avec HIV et pr\u00e9sentant un exc\u00e8s de graisse abdominale dans le contexte d'un traitement antir\u00e9troviral.<\/p>
Ce contexte est important car la lipodystrophie associ\u00e9e \u00e0 HIV n'est pas interchangeable avec l'ob\u00e9sit\u00e9 g\u00e9n\u00e9rale et le tissu adipeux visc\u00e9ral mesur\u00e9 par imagerie n'est pas le m\u00eame crit\u00e8re d'\u00e9valuation que la perte de poids globale.<\/p>
Ce que l\u2019\u00e9tude randomis\u00e9e d\u2019un mois 12 a r\u00e9v\u00e9l\u00e9<\/h2>
Une \u00e9tude randomis\u00e9e contr\u00f4l\u00e9e par placebo impliquant des participants \u00e0 404 a utilis\u00e9 le tissu adipeux visc\u00e9ral comme crit\u00e8re d'\u00e9valuation principal. Les enqu\u00eateurs ont signal\u00e9 une r\u00e9duction de la graisse visc\u00e9rale au cours de la phase randomis\u00e9e initiale et une persistance chez les participants qui ont poursuivi le traitement. Les am\u00e9liorations ont \u00e9t\u00e9 perdues apr\u00e8s le passage de la t\u00e9samor\u00e9line au placebo, ce qui permet de clarifier la d\u00e9pendance de l'effet observ\u00e9 sur une exposition continue dans ce protocole.<\/p>
Une \u00e9tude randomis\u00e9e plus petite a \u00e9galement \u00e9valu\u00e9 la graisse h\u00e9patique et le tissu adipeux visc\u00e9ral. Ses r\u00e9sultats \u00e9taient exploratoires pour les r\u00e9sultats li\u00e9s au foie et ne doivent pas \u00eatre convertis en une indication approuv\u00e9e pour une maladie h\u00e9patique.<\/p>
Population<\/strong>Adultes avec HIV et exc\u00e8s de graisse abdominale<\/span><\/div>
Mesure primaire<\/strong>Tissu adipeux visc\u00e9ral par imagerie<\/span><\/div>
Limite importante<\/strong>Il ne s'agit pas d'une population ou d'une indication g\u00e9n\u00e9rale de gestion du poids.<\/span><\/div><\/div><\/div>
Limites d'\u00e9tiquettes qui appartiennent \u00e0 chaque r\u00e9sum\u00e9<\/h2>
L'\u00e9tiquette 2025 EGRIFTA WR identifie une formulation et une indication sp\u00e9cifiques approuv\u00e9es. Il note \u00e9galement que la s\u00e9curit\u00e9 cardiovasculaire \u00e0 long terme n'a pas \u00e9t\u00e9 \u00e9tablie et que le produit n'est pas indiqu\u00e9 pour la gestion de la perte de poids. Ces limitations font partie de la preuve et non des petits caract\u00e8res facultatifs.<\/p>","protected":false},"excerpt":{"rendered":"
Une revue fond\u00e9e sur des preuves d'essais sur la t\u00e9samor\u00e9line chez des adultes pr\u00e9sentant une accumulation de graisse abdominale associ\u00e9e \u00e0 HIV, y compris les crit\u00e8res d'\u00e9valuation, les limites et le contexte \u00e9tiquet\u00e9 FDA.<\/p>","protected":false},"author":1,"featured_media":623,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"pim_family_ids":"367","pim_article_type":"Clinical evidence review","pim_evidence_level":"Randomized controlled human trials and FDA labeling","pim_reviewer":"NHD evidence editorial workflow","pim_reviewed_date":"2026-08-27","pim_editorial_note":"Source-checked against the linked primary or authoritative records on 2026-08-27. This is an evidence summary, not independent peer review, medical advice or validation of a catalog lot.","pim_review_status":"reviewed","pim_review_reason":"At least two linked primary or authoritative records and an explicit evidence boundary are present.","pim_creation_method":"The editorial workflow starts with linked peer-reviewed papers, trial registries or regulatory records; extracts the population or model, endpoints, numerical results and limitations; and separates the studied intervention from catalog material. AI-assisted drafting was used to structure the first version. Claims, figures, evidence labels and limitations were checked against the linked records in the site editorial workflow. This is not independent peer review.","pim_sources":"[{\"title\":\"Randomized tesamorelin trial with 12-month extension\",\"url\":\"https:\/\/pubmed.ncbi.nlm.nih.gov\/20101189\/\",\"note\":\"Primary human trial; PMID 20101189.\"},{\"title\":\"Randomized trial of visceral and liver fat outcomes\",\"url\":\"https:\/\/pubmed.ncbi.nlm.nih.gov\/25038357\/\",\"note\":\"Exploratory liver-fat evidence; PMID 25038357.\"},{\"title\":\"FDA EGRIFTA WR prescribing information\",\"url\":\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/022505s020lbl.pdf\",\"note\":\"Approved-product indication and limitations.\"}]","footnotes":""},"categories":[18],"tags":[],"class_list":["post-453","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-evidence-reviews"],"yoast_head":"\n
Tesamorelin and HIV-Associated Lipodystrophy: What Randomized Trials Measured - NHD<\/title>\n<meta name=\"description\" content=\"An evidence-led review of tesamorelin trials in adults with HIV-associated abdominal fat accumulation, including endpoints, limits and FDA-labeled context.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nhdbio.com\/fr\/essais-cliniques-randomises-sur-la-tesamoreline-et-la-lipodystrophie-liee-au-vih\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tesamorelin and HIV-Associated Lipodystrophy: What Randomized Trials Measured\" \/>\n<meta property=\"og:description\" content=\"An evidence-led review of tesamorelin trials in adults with HIV-associated abdominal fat accumulation, including endpoints, limits and FDA-labeled context.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nhdbio.com\/fr\/essais-cliniques-randomises-sur-la-tesamoreline-et-la-lipodystrophie-liee-au-vih\/\" \/>\n<meta property=\"og:site_name\" content=\"NHD\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-27T10:31:11+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-28T07:31:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/tesamorelin-hiv-lipodystrophy-randomized-trials-featured-v2.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1536\" \/>\n\t<meta property=\"og:image:height\" content=\"960\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"NHD Technical Team\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Peptide Raw Materials and Custom Peptide Synthesis\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"NHD Technical Team\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/tesamorelin-hiv-lipodystrophy-randomized-trials\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/tesamorelin-hiv-lipodystrophy-randomized-trials\\\/\"},\"author\":{\"name\":\"NHD Technical Team\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\"},\"headline\":\"Tesamorelin and HIV-Associated Lipodystrophy: What Randomized Trials Measured\",\"datePublished\":\"2026-08-27T10:31:11+00:00\",\"dateModified\":\"2026-08-28T07:31:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/tesamorelin-hiv-lipodystrophy-randomized-trials\\\/\"},\"wordCount\":344,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/tesamorelin-hiv-lipodystrophy-randomized-trials\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/tesamorelin-hiv-lipodystrophy-randomized-trials-featured-v2.webp\",\"articleSection\":[\"Evidence Reviews\"],\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/tesamorelin-hiv-lipodystrophy-randomized-trials\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/tesamorelin-hiv-lipodystrophy-randomized-trials\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/tesamorelin-hiv-lipodystrophy-randomized-trials\\\/\",\"name\":\"Tesamorelin and HIV-Associated Lipodystrophy: What Randomized Trials Measured - NHD\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/tesamorelin-hiv-lipodystrophy-randomized-trials\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/tesamorelin-hiv-lipodystrophy-randomized-trials\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/tesamorelin-hiv-lipodystrophy-randomized-trials-featured-v2.webp\",\"datePublished\":\"2026-08-27T10:31:11+00:00\",\"dateModified\":\"2026-08-28T07:31:46+00:00\",\"description\":\"An evidence-led review of tesamorelin trials in adults with HIV-associated abdominal fat accumulation, including endpoints, limits and FDA-labeled context.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/tesamorelin-hiv-lipodystrophy-randomized-trials\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/tesamorelin-hiv-lipodystrophy-randomized-trials\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/tesamorelin-hiv-lipodystrophy-randomized-trials\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/tesamorelin-hiv-lipodystrophy-randomized-trials-featured-v2.webp\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/tesamorelin-hiv-lipodystrophy-randomized-trials-featured-v2.webp\",\"width\":1536,\"height\":960,\"caption\":\"Article-specific editorial image.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/tesamorelin-hiv-lipodystrophy-randomized-trials\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nhdbio.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Tesamorelin and HIV-Associated Lipodystrophy: What Randomized Trials Measured\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"name\":\"NHD\",\"description\":\"Peptide Raw Materials and Custom Peptide Synthesis\",\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nhdbio.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\",\"name\":\"NHD\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"width\":2172,\"height\":724,\"caption\":\"NHD\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\",\"name\":\"NHD Technical Team\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"caption\":\"NHD Technical Team\"},\"description\":\"NHD Technical Team maintains research-use catalog documentation and evidence summaries. Reviewed articles link to peer-reviewed papers, trial registries and regulatory records, retain null findings and study limitations, and distinguish published interventions from catalog materials. AI-assisted drafting may be used for structure; source links and evidence boundaries remain visible. This work is not independent peer review or medical advice.\",\"sameAs\":[\"https:\\\/\\\/nhdbio.com\"],\"url\":\"https:\\\/\\\/nhdbio.com\\\/fr\\\/author\\\/qianmiao-technical-team\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Lipodystrophie associ\u00e9e \u00e0 Tesamorelin et HIV\u00a0: ce que les essais randomis\u00e9s ont mesur\u00e9 - NHD","description":"Une revue fond\u00e9e sur des preuves d'essais sur la t\u00e9samor\u00e9line chez des adultes pr\u00e9sentant une accumulation de graisse abdominale associ\u00e9e \u00e0 HIV, y compris les crit\u00e8res d'\u00e9valuation, les limites et le contexte \u00e9tiquet\u00e9 FDA.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nhdbio.com\/fr\/essais-cliniques-randomises-sur-la-tesamoreline-et-la-lipodystrophie-liee-au-vih\/","og_locale":"fr_FR","og_type":"article","og_title":"Tesamorelin and HIV-Associated Lipodystrophy: What Randomized Trials Measured","og_description":"An evidence-led review of tesamorelin trials in adults with HIV-associated abdominal fat accumulation, including endpoints, limits and FDA-labeled context.","og_url":"https:\/\/nhdbio.com\/fr\/essais-cliniques-randomises-sur-la-tesamoreline-et-la-lipodystrophie-liee-au-vih\/","og_site_name":"NHD","article_published_time":"2026-08-27T10:31:11+00:00","article_modified_time":"2026-08-28T07:31:46+00:00","og_image":[{"width":1536,"height":960,"url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/tesamorelin-hiv-lipodystrophy-randomized-trials-featured-v2.webp","type":"image\/webp"}],"author":"NHD Technical Team","twitter_card":"summary_large_image","twitter_description":"Peptide Raw Materials and Custom Peptide Synthesis","twitter_misc":{"\u00c9crit par":"NHD Technical Team","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nhdbio.com\/tesamorelin-hiv-lipodystrophy-randomized-trials\/#article","isPartOf":{"@id":"https:\/\/nhdbio.com\/tesamorelin-hiv-lipodystrophy-randomized-trials\/"},"author":{"name":"NHD Technical Team","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1"},"headline":"Tesamorelin and HIV-Associated Lipodystrophy: What Randomized Trials Measured","datePublished":"2026-08-27T10:31:11+00:00","dateModified":"2026-08-28T07:31:46+00:00","mainEntityOfPage":{"@id":"https:\/\/nhdbio.com\/tesamorelin-hiv-lipodystrophy-randomized-trials\/"},"wordCount":344,"commentCount":0,"publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"image":{"@id":"https:\/\/nhdbio.com\/tesamorelin-hiv-lipodystrophy-randomized-trials\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/tesamorelin-hiv-lipodystrophy-randomized-trials-featured-v2.webp","articleSection":["Evidence Reviews"],"inLanguage":"fr-FR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/nhdbio.com\/tesamorelin-hiv-lipodystrophy-randomized-trials\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/nhdbio.com\/tesamorelin-hiv-lipodystrophy-randomized-trials\/","url":"https:\/\/nhdbio.com\/tesamorelin-hiv-lipodystrophy-randomized-trials\/","name":"Lipodystrophie associ\u00e9e \u00e0 Tesamorelin et HIV\u00a0: ce que les essais randomis\u00e9s ont mesur\u00e9 - NHD","isPartOf":{"@id":"https:\/\/nhdbio.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nhdbio.com\/tesamorelin-hiv-lipodystrophy-randomized-trials\/#primaryimage"},"image":{"@id":"https:\/\/nhdbio.com\/tesamorelin-hiv-lipodystrophy-randomized-trials\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/tesamorelin-hiv-lipodystrophy-randomized-trials-featured-v2.webp","datePublished":"2026-08-27T10:31:11+00:00","dateModified":"2026-08-28T07:31:46+00:00","description":"Une revue fond\u00e9e sur des preuves d'essais sur la t\u00e9samor\u00e9line chez des adultes pr\u00e9sentant une accumulation de graisse abdominale associ\u00e9e \u00e0 HIV, y compris les crit\u00e8res d'\u00e9valuation, les limites et le contexte \u00e9tiquet\u00e9 FDA.","breadcrumb":{"@id":"https:\/\/nhdbio.com\/tesamorelin-hiv-lipodystrophy-randomized-trials\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nhdbio.com\/tesamorelin-hiv-lipodystrophy-randomized-trials\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/nhdbio.com\/tesamorelin-hiv-lipodystrophy-randomized-trials\/#primaryimage","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/tesamorelin-hiv-lipodystrophy-randomized-trials-featured-v2.webp","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/tesamorelin-hiv-lipodystrophy-randomized-trials-featured-v2.webp","width":1536,"height":960,"caption":"Article-specific editorial image."},{"@type":"BreadcrumbList","@id":"https:\/\/nhdbio.com\/tesamorelin-hiv-lipodystrophy-randomized-trials\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nhdbio.com\/"},{"@type":"ListItem","position":2,"name":"Tesamorelin and HIV-Associated Lipodystrophy: What Randomized Trials Measured"}]},{"@type":"WebSite","@id":"https:\/\/nhdbio.com\/#website","url":"https:\/\/nhdbio.com\/","name":"NHD","description":"Mati\u00e8res premi\u00e8res peptidiques et synth\u00e8se sur mesure","publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nhdbio.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/nhdbio.com\/#organization","name":"NHD","url":"https:\/\/nhdbio.com\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","width":2172,"height":724,"caption":"NHD"},"image":{"@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1","name":"\u00c9quipe technique NHD","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","caption":"NHD Technical Team"},"description":"L'\u00e9quipe technique NHD maintient la documentation du catalogue d'utilisation de la recherche et les r\u00e9sum\u00e9s des preuves. Les articles examin\u00e9s renvoient \u00e0 des articles \u00e9valu\u00e9s par des pairs, \u00e0 des registres d'essais et \u00e0 des dossiers r\u00e9glementaires, conservent les r\u00e9sultats nuls et les limites des \u00e9tudes, et distinguent les interventions publi\u00e9es des documents du catalogue. Le dessin assist\u00e9 par AI peut \u00eatre utilis\u00e9 pour la structure\u00a0; les liens vers les sources et les limites des preuves restent visibles. Ce travail ne constitue pas un examen ind\u00e9pendant par des pairs ni un avis m\u00e9dical.","sameAs":["https:\/\/nhdbio.com"],"url":"https:\/\/nhdbio.com\/fr\/author\/qianmiao-technical-team\/"}]}},"_links":{"self":[{"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/posts\/453","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/comments?post=453"}],"version-history":[{"count":1,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/posts\/453\/revisions"}],"predecessor-version":[{"id":518,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/posts\/453\/revisions\/518"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/media\/623"}],"wp:attachment":[{"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/media?parent=453"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/categories?post=453"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/tags?post=453"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
![\"Un](\"http:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/tesamorelin-hiv-visceral-fat-research.png\")